12月15日，康哲药业（00867）发布公告，旗下德镁医药有限公司的创新口服小分子JAK1抑制剂Povorcitinib已获中国国家药品监督管理局批准纳入突破性治疗品种名单，适应症为成人患者非节段型白癜风。这一认定将加速该产品的研发与审评进程，若在中国获批上市，有望为约820万非节段型白癜风患者提供新的治疗选择。
Povorcitinib目前正在进行的3期临床试验包括非节段型白癜风、中重度化脓性汗腺炎和结节性痒疹，且有2期试验针对哮喘。公告提到，该产品在全球多中心2b期临床研究中显示出显著疗效，治疗24周后，接受Povorcitinib治疗的患者全身皮损显著复色，且长期使用耐受性良好。
此外，德镁医药已获得NMPA的临床试验批准，启动产品在中国的临床开发工作。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.